Prophylaxis against fungal infections in transplant recipients: Possible approaches

BioDrugs

Volumn 11, Issue 5, 1999, Pages 309-318

  Tollemar, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; LIPOSOME; NYSTATIN;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MYCOSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0032905463     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911050-00003     Document Type: Review

References (54)

1. Rubin RH, Wolfson JS, Cosimi AD, et al. Infection in the renal transplant patient. Am J Med 1981; 70: 405-11
2. Shah PM, Just KG. Fungal infections in organ transplantation. In Holmberg K, Meyer R, editors. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989: 71-8
3. Dummer JS, Hardy A, Poorsatter A, et al. Early infections in kidney, heart, and liver transplant recipientson cyclosporinc. Transplatation 1983; 36: 259-67
4. Bodey GP. Candidiasis in cancer patients. Am J Med 1984; 77 Suppl. 4 D: 13-9
5. Winston DJ, Gale RP, Meyer DV, et al. Infectious complications of human bone marrow transplantation. Medicine 1979; 58: 1-31
6. Denning DW. Epidennology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28 Suppl. B: 1-16
7. Verfaillie C, Weisdorf D, Haake R, et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-84
8. Janknegt R, de Marie S, Baaker-Woudenberg IAJM, et al. Liposomal and lipid formulations of amphotericin B clinical pharmacokinetics. Clin Pharmacokinet 1992; 23 (4): 279-91
9. Tollemar J, Ringdén O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Saf 1995; 13 (4): 207-18
10. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987; 2: 408-16
11. Odds FC. Candida and candidosis: a review and bibliography. 2nd ed. London: Balliére Tindall, 1988
12. Hay RJ. Dimorphism and candidosis: clinical and therapeutic implications. Diagnosis and treatment of mycoses. In: Vanden Bossehe H, Kerridge D, Odds FC, editors. Dimorphic fungi in biology and medicine. New York: Plenum Press 1993; 373-9
13. Krause W, Mathies H, Wulf K. Fungaemia and fungiuria after oral administration of Candida albicans. Lancet 1969; 1: 598-599
14. Powles RL, Milliken S. The prophylaxis of fungal infections. J Anti Chemotherapy 1991; 28 Suppl. A: 97-103
15. Meunier F. Fungal infections in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. New York: Plenum Press, 1988: 193-220
16. Hay RJ. Clinical manifestations and management of cryptococcosis in the compromised patient. In: Warnock DW, Richardson MD, editors. Fungal infection in the compromised patient. 2nd ed. Chichester: John Wiley & Sons Ltd 1991: 85-116
17. Tollemar J, Ringdén O, Boström L, et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-41
18. Ekelöf Andström E, Ringdén O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B -in allogeneic bone marrow transplant recipients. Mycoses 1996; 39: 185-93
19. Wajszczuk CP, Dummer JS, HO M, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-53
20. Tollemar J, Ericzon, B-G. Invasive candida albicans infections in orthotopic liver graft recipients. Incidence and risk-factors. Clin Transplant 1991; 5: 306-12
21. Masur H, Cheigh JS, Stubenbord WT. Infection following renal transplantation: a changing pattern. Rev Infect Dis 1982; 4: 1208-19
22. Baumgartner WA, Peitz BA, Oyer PE. et al. Cardiac homotransplantation. Curr Probl Surg 1979; 16: 1-61
23. Dummer JS, Montero CG, Griffith BP, et al. Infections in heart lung transplant recipients. Transplantation 1986; 41: 725-9
24. Hesse UJ, Sutherland DER, Najarian JS, et al. Intra-abdominal infections in pancreas transplant recipients. Ann Surg 1986; 203: 153-62
25. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment and outcome. J Am Coll Surg 1996; 183: 307-16
26. Reyes J, Abu-Elmagd K, Tzakis A, et al. Infectious complication after human small bowel transplantation. Transplant Proc 1992; 24: 1249-50
27. Kosne S, Abu-Elmagd K, Hutson W, et al. Invasive fungal infections after adult small bowel transplantation (SBTX) Abstract no: O34 At: 5th International Symposium on Small Intestinal Transplantation, Cambridge, UK, 1997 Jul 31-Aug 2
28. Rifkind D, Marcheioro TL, Schneck SA, et al. Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Am J Med 1967; 43: 28-38
29. Tollemar J, Ekelöf-Andström E, Ringden O. Seven years experience with liposomal Amphotericin B (AmBisome) treatment in [2] solid organ transplant recipients, efficacy and safety [abstract 22]. At: Focus on fungal infections 7, San Antonio, USA, 1947 13-14 Mar
30. Tollemar J, Fungal infections in solid organ transplant recipients. In: Bowden R, Ljungman P, Paya C, editors. Transplant infections transplantation. Philadelphia: Lippincott-Raven Publishers, 1998: Chapter 24, 339-50
31. Wade CW, Schimpff SC. Epidemiology and prevention of infection in the compromised host. In Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. New York: Plenum medical book company 1988: 5-40
32. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51
33. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52
34. Winston DJ, Pakrasi A, Busuttil RW, et al. Fluconazole prophylaxis of fungal infections in liver transplant recipients: Results of a placebo-controlled, double -blind trial [abstract 146]. At: The Ninth International Symposium on Infections in the immunocompromised Host, 1996 23-26 Jun; Assisi, Italy
35. Tollemar, J, Höckerstedt, K, Ericzon, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo controlled study. Transplantation 1995; 59 1: 45-50
36. Klingspor L, Stintzing G, Fasth A, et al. Deep candida infection in children recieving allogeneic bone marrow transplants: incidence, risk-factors and diagnosis. Bone Marrow Transplant 1996; 17: 1043-9
37. Tollemar J, Höckerstedt K, Ericzon B-G et al. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: longterm results of a randomized, placebo controlled trial. Transplant Proc 1995; 27: 1195-8
38. Van der Waaij D, Vossen JM, Hartgrink CA, et al. Polyene antibiotics in the prevention of Candida albicans colonization in the digestive tract of patients with severely decreased resistance to infections. In: Van der Waaij D, Verhoef J, editors. New criteria for antimicrobial therapy: maintainance of digestive tract colonization resistance. Amsterdam: Excerpta Medica 1979; 135-44
39. Schimpff SC, Greene WH, Young VM, et al. Infection preventionin acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975; 82: 351-8
40. Ezdinli EZ, O'Sullivan DD, Wasser LP, et al. Oral amphotericin for candidiasis in patients hematological neoplasms: an autopsy study. JAMA 1979; 242: 258-60
41. Buchanan AG, Riben PD, Raynor EN, et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med 1985; 8: 139-47
42. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989; 64: 555-64
43. Meunier-Carpentier F, Snoeck R, Gerain J, et al. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia [letter]. N Engl J Med 1984; 311: 1056
44. Conneally E, Cafferky MT, Daly PA, et al. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-6
45. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72
46. Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-8
47. Todeschini G, Murari C, Bonesi R, et al. Oral itraconazol plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12: 614-8
48. Shulman H, Striker G, Deeg J, et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation. N Engl J Med 1981; 305: 1392-5
49. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous Amphotericin B in neutropenic autologous bone marrow transplant recipients. JID 1992; 165: 891-7
50. Rousey SR, Russler S, Gottlieb M, et al. Low-dose Amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-92
51. Mora NP, Klintmalm G, Solomon RM, et al. Selective Amphotericin B prophylaxis in the reduction of fungal infections after liver transplant. Transplant Proc 1993 Feb; 24 (1): 154-5
52. Tollemar J, Ringdén O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-82
53. Björkholm M. Antifungal chemoprophylaxis in patients with neutropenia and the aquired immunodeficiency syndrome. In Prophylaxis and treatmet of invasive fungal infections. Swedish Medical Product Agency & Norwegian Medicines Control Authority, Workshop 2 1995: 135-46
54. Offner F, Cordonnier C, Marinus A, et al. Influence of prior aspergillosis on outcome of bone marrow transplantation (BMT) [abstract 92]. At: The 22nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 1996 3-7 Mar